Methods A multidisciplinary working group drafted a management algorithm for advanced
urothelial carcinoma using “consensus development conference” methodology. A targeted …

In recent years the introduction of immunotherapy has importantly changed the treatment
landscape of advanced urothelial carcinoma. Several immune checkpoint inhibitors are now …

Evolving systemic management of urothelial cancers : Current Opinion in Oncology Evolving
systemic management of urothelial cancers : Current Opinion in Oncology Log in or Register …

The evolving treatment landscape of advanced urothelial carc... : Current Opinion in Oncology
The evolving treatment landscape of advanced urothelial carcinoma : Current Opinion in …

Despite recent advances in the identification of genomic alterations that lead to urothelial
oncogenesis in vitro, patients with advanced urothelial carcinomas continue to have poor …

Background Patients with advanced urothelial carcinoma (UC) have poor outcomes, with 5-
year survival rates of< 5% for those with metastatic, stage IV disease. We have reviewed …

Urothelial carcinoma of the bladder comprises a spectrum of illnesses ranging from
nonmuscle-invasive to muscle-invasive to advanced/metastatic disease. Each of these …

The current standard of care for metastatic urothelial carcinoma is cisplatin-based
chemotherapy but treatment is generally not curative. Mechanisms of resistance to …

The treatment of advanced urothelial cancer of the bladder has evolved substantially during
recent years. Chemotherapy has been the mainstay of treatment and confers survival …

The standard of care for patients with local advanced or metastatic urothelial carcinoma is
chemotherapy. However, results with this are rather disappointing, and validated prognostic …